Xeltis’ innovative technology platform has been branded RestoreX.
Xeltis’ RestoreX technology platform comprises the first ever bioabsorbable heart valves and blood vessels that enable cardiovascular restoration. After implantation, Xeltis’ devices enable the body to restore the part of the heart they replace with the patient’s own tissue. This novel therapeutic approach is called Endogenous Tissue Restoration (ETR).
To date, the RestoreX technology platform comprises a pulmonary valve in clinical trials; an aortic valve in preclinical phase and additional applications under investigation.
“RestoreX has the potential to become synonymous with cardiovascular treatment. The clinical benefits that may be achieved through ETR make the RestoreX technology a potential game-changer,” said Laurent Grandidier, Xeltis CEO.
